StemCell Therapy

GB Sciences, Inc. (OTCQB:GBLX) announced filing the second in a series of patent applications for life science inventions by its wholly-owned subsidiary, Growblox Life Sciences, LLC.

Inflammatory disorders represent a serious health and economic burden in the US with over $200 billion spent annually. GB Sciences novel cannabis-based therapies could significantly help both patients and society. According to the CDC, arthritis affects 22.7% (52.5 million) of adults in the US (2010-2012), and the prevalence is projected to increase to an estimated 26% (78 million of the projected total adult population) by 2040. The total costs associated with arthritis were $128 billion in 2003, and they have been increasing over time. Additionally, 8.6% (7 million) children and 7.4% (17.8 million) adults had asthma (2014), which costs the US $56 billion per year. Inflammatory Bowel Disease (IBD), which includes Crohns disease and ulcerative colitis) affected between 1 and 1.3 million people in the US (2007). Per the CDC, IBD is an expensive, chronic disease, which cost the US $11.8 billion in 2008, despite the lower prevalence rates.

The current provisional patent application covers cannabinoid-containing complex mixtures (CCCM) capable of preventing and treating a spectrum of inflammatory disorders. The application focuses on the use of CCCM to disrupt the signaling pathways in certain immune cells that lead to the initiation and maintenance of inflammatory responses. Both common and uncommon inflammatory disorders, ranging from chronic arthritis to acute responses to insect stings, are likely to be effectively targeted by this therapeutic approach.

Although inflammatory reactions are a necessary part of human immunity in some situations (e.g., fighting pathogens), humans (and animals) suffer from multiple inflammatory disorders involving hyper-inflammatory responses. Our novel CCCM strategically target multiple arms of these hyper-inflammatory responses in parallel for maximal effect, rather than inhibiting a single arm like other commonly available anti-inflammatory therapies, explains Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences. For example, anti-histamines are partly effective, but leave untouched those inflammatory pathways that lead to release of other pro-inflammatory mediators, such as bioactive lipids and cytokines. GB Sciences approach is to simultaneously target as many inflammatory outputs as possible with our CCCM, leading to more comprehensive relief from tissue inflammation.

John Poss, CEO, GB Sciences states: GB Sciences is committed to developing cannabis-based therapies for inflammatory disorders that affect large numbers of patients (arthritis, dermatitis, allergic asthma, eczema, IBD, Crohns disease, etc.). Our CCCM products will be developed to the same efficacy and safety standards as other commercially available anti-inflammatory therapies; however, cannabis-based medicines often have more favorable side effect profiles than traditional pharmaceuticals.

About GB Sciences, Inc.

GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Companys goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://growblox.com

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as expects, intends, plans, may, could, should, anticipates, likely, believes and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Companys belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Companys control. It is possible that the Companys actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Companys business and financial and other results, are contained in the Companys filings with the Securities and Exchange Commission, available at http://www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note: Although the Companys research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information

Corporate: GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118 866-721-0297, or Liz Bianco Publicity Director, liz@gbsciences.com, http://growblox.com Investors: John Poss, j.poss@gbsciences.com

creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://growblox.com

SOURCE Growblox Sciences, Inc.

See the original post here:
GB Sciences Files Patent Application for the Treatment of Chronic Arthritis, Crohn's Disease, Inflammatory Bowel ... - Investing News Network (press...

This entry was posted on February 7, 2017 at 2:51 am and is filed under Arthritis. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |